Tyrosine hydroxylase (TH) neurons are catecholaminergic neurons that express the rate-limiting enzyme in dopamine, norepinephrine, and epinephrine synthesis. TH catalyzes the conversion of L-tyrosine to L-DOPA, the committed step in catecholamine biosynthesis. These neurons include the dopaminergic neurons of the substantia nigra and ventral tegmental area, noradrenergic neurons of the locus coeruleus, and adrenergic neurons in the medulla.[1]
The TH gene is located on chromosome 11p15.5 and encodes a 497-amino acid enzyme:[2]
| Domain | Position | Function |
|---|---|---|
| N-terminal regulatory | 1-155 | Phosphorylation sites |
| Catalytic core | 156-497 | Iron-dependent hydroxylase |
| C-terminal | 470-497 | Substrate binding |
TH activity is regulated by multiple mechanisms:[3]
Phosphorylation sites:
Cofactors and substrates:
Feedback inhibition:
Nigrostriatal pathway (A9):[4]
Mesolimbic pathway (A10):
Mesocortical pathway:
Tuberoinfundibular pathway (A12):
Locus coeruleus (A6):[5]
Lateral tegmental field:
C1 neurons (rostral ventrolateral medulla):
C2 neurons (dorsal medulla):
TH neurons are central to PD pathophysiology:[6]
SNpc TH neuron loss:
TH expression changes:
L-DOPA therapy:
TH as biomarker:
Noradrenergic TH neurons affected in AD:[7]
Locus coeruleus degeneration:
Cortical norepinephrine depletion:
Neuroinflammation:
MSA shows widespread TH abnormalities:[8]
Striatonigral degeneration:
Autonomic failure:
TH pathology in DLB:[9]
| Strategy | Mechanism | Limitation |
|---|---|---|
| L-DOPA/carbidopa | Dopamine precursor | Motor complications |
| BH4 supplementation | Cofactor replacement | Limited efficacy |
| Tyrosine loading | Substrate provision | Minimal effect |
TH gene delivery:
Neurotrophic support:
Strategies to preserve TH neurons:[10]
Tyrosine hydroxylase neurons are essential for catecholamine synthesis throughout the brain. Their selective vulnerability in Parkinson's disease makes them a central focus of neurodegeneration research. Understanding TH regulation, cofactor requirements, and protective mechanisms informs both symptomatic treatment (L-DOPA) and disease-modifying strategies (neuroprotection, gene therapy).
Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Archives of Biochemistry and Biophysics. 2011. ↩︎
Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase: the initial step in norepinephrine biosynthesis. Journal of Biological Chemistry. 1964. ↩︎
Tekin I, Roskoski R Jr, Carkaci-Salli N, Vrana KE. Complex molecular regulation of tyrosine hydroxylase. Journal of Neural Transmission. 2014. ↩︎
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999. ↩︎
Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of physiological state-by-state-dependent neural processes. Brain Research Reviews. 2003. ↩︎
Hornykiewicz O. Dopamine miracle: from brain chemistry to neurodegenerative disorders. Movement Disorders. 2009. ↩︎
Heneka MT, Ramanathan M, Jacobs AH, et al. Locus coeruleus degeneration and Alzheimer's disease. Neurobiology of Aging. 2006. ↩︎
Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Movement Disorders. 1997. ↩︎
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015. ↩︎
Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease. Lancet Neurology. 2014. ↩︎